A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Eisai Inc.
Inhibrx Biosciences, Inc
UNICANCER
National University Hospital, Singapore
Nurix Therapeutics, Inc.
DEKA Biosciences
Jazz Pharmaceuticals
Eli Lilly and Company
Actuate Therapeutics Inc.
AbbVie
Sumitomo Pharma America, Inc.
Indiana University
Blokhin's Russian Cancer Research Center
Lumos Pharma
Shenzhen Hornetcorn Bio-technology Company, LTD
City of Hope Medical Center
Hanmi Pharmaceutical Company Limited
GlaxoSmithKline
Seattle Cancer Treatment and Wellness Center